(R)-1,3-dimethyl-2-piperidone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (R)-1,3-dimethyl-2-piperidone
• 英文别名: (3R)-1,3-dimethylpiperidin-2-one
• 化学式: C₇H₁₃NO
• 分子量: 127.186
• InChiKey: RJLKIAGOYBARJG-ZCFIWIBFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1,3-二甲基-2(1h)-吡啶酮 在 [bis(2-methylallyl)cycloocta-1,5-diene]ruthenium(II) 、 1,3-bis-(1(R)-phenyl-ethyl)-4,5-dihydro-3H-imidazol-1-ium tetrafluoroborate 、 potassium tert-butylate 、 氢气 作用下， 以 2-甲基-2-丁醇 、 正己烷 为溶剂， -10.0 ℃ 、12.0 MPa 条件下， 反应 24.0h， 以64%的产率得到
  参考文献：
  名称：

  Asymmetric Homogeneous Hydrogenation of 2-Pyridones

  摘要：

  An asymmetric homogeneous hydrogenation of 2(1H)-pyridones has been developed, using a ruthenium complex bearing two chiral N-heterocyclic carbene (NHC) ligands. To the best of our knowledge, the presented reaction is the first example of a homogeneous asymmetric conversion of 2-pyridones into the corresponding enantioenriched 2-piperidones.

  DOI：

  10.1055/s-0034-1378703

文献信息

• HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF
  申请人：Merck Patent GmbH

  公开号：US20170081307A1

  公开（公告）日：2017-03-23

  The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
• ACC INHIBITORS AND USES THEREOF
  申请人：Gilead Apollo, LLC

  公开号：US20170145028A1

  公开（公告）日：2017-05-25

  The present invention provides compounds useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, and methods of using the same.
• PYRAZOLOPYRIMIDINE COMPOUNDS AS JAK INHIBITORS
  申请人：Genentech, Inc.

  公开号：US20200339604A1

  公开（公告）日：2020-10-29

  Compounds and salts thereof that are useful as JAK kinse inhibitors are described herein. Also provided are pharmaceutical compositions that include such a JAK inhibitor and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient.